2Quinazolin4(3H)one derivatives as dual EGFR and VEGFR2 inhibitors: Design, synthesis, molecular docking and anticancer activity

Pharmacology, Toxicology and Pharmaceutical Science

1. Epidermal Growth Factor Receptor 100%
2. Malignant Neoplasm 50%
3. Tumor Growth 13%
4. Vasculotropin 10%
5. Anticarcinogen 10%
6. Therapeutic Effect 6%
7. Neovascularization (Pathology) 6%
8. Protein Tyrosine Kinase 6%
9. Mortality Rate 6%
10. Gamma Urogastrone 6%
11. Phosphotransferase Inhibitor 6%
12. Drug Resistance 6%
13. Anticancer Drug 6%
14. Cancer Incidence 6%
15. Antiangiogenic Therapy 6%